Skip to main content

Table 3 Changes of CRP, VEGF and RI

From: Efficacy of wIRA in the treatment of sacroiliitis in male patients with ankylosing spondylitis and its effect on serum VEGF levels

  Before the first stage After the first stage After the second stage
CRP (mg/L)
 Treatment regimen A 30.21 ± 6.98 27.33 ± 6.23a 29.96 ± 6.21
 Treatment regimen B 30.03 ± 8.33 29.55 ± 7.71 26.83 ± 6.08
VEGF (pg/ml)
 Treatment regimen A 180.22 ± 18.51 178.32 ± 16.10b 179.63 ± 17.59
 Treatment regimen B 182.87 ± 23.31 183.12 ± 21.40c 180.45 ± 20.49
RI (0~1)
 Treatment regimen A 0.53 ± 0.05 0.85 ± 0.04d 0.63 ± 0.04
 Treatment regimen B 0.54 ± 0.05 0.55 ± 0.06 0.83 ± 0.04
  1. CRP C-reactive protein, VEGF vascular endothelial growth factor, RI resistance index
  2. aCompared with that before the first stage (P = 0.032)
  3. bCompared with that before the first stage (P = 0.230)
  4. cCompared with that before the first stage (P = 0.120)
  5. dCompared with that before the first stage (P < 0.001)